Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Summary
To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia
Official title: A Multicenter, Open-label, Single Arm Phase IV Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
Key Details
Gender
All
Age Range
2 Years - 10 Years
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2022-08-20
Completion Date
2025-12-12
Last Updated
2026-08-06
Healthy Volunteers
No
Conditions
Interventions
Recombinant human growth hormone
Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
Locations (1)
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China